Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart
Xing Fu, … , Burns C. Blaxall, Jeffery D. Molkentin
Xing Fu, … , Burns C. Blaxall, Jeffery D. Molkentin
Published April 16, 2018
Citation Information: J Clin Invest. 2018;128(5):2127-2143. https://doi.org/10.1172/JCI98215.
View: Text | PDF
Research Article Cardiology

Specialized fibroblast differentiated states underlie scar formation in the infarcted mouse heart

  • Text
  • PDF
Abstract

Fibroblasts are a dynamic cell type that achieve selective differentiated states to mediate acute wound healing and long-term tissue remodeling with scarring. With myocardial infarction injury, cardiomyocytes are replaced by secreted extracellular matrix proteins produced by proliferating and differentiating fibroblasts. Here, we employed 3 different mouse lineage-tracing models and stage-specific gene profiling to phenotypically analyze and classify resident cardiac fibroblast dynamics during myocardial infarction injury and stable scar formation. Fibroblasts were activated and highly proliferative, reaching a maximum rate within 2 to 4 days after infarction injury, at which point they expanded 3.5-fold and were maintained long term. By 3 to 7 days, these cells differentiated into myofibroblasts that secreted abundant extracellular matrix proteins and expressed smooth muscle α-actin to structurally support the necrotic area. By 7 to 10 days, myofibroblasts lost proliferative ability and smooth muscle α-actin expression as the collagen-containing extracellular matrix and scar fully matured. However, these same lineage-traced initial fibroblasts persisted within the scar, achieving a new molecular and stable differentiated state referred to as a matrifibrocyte, which was also observed in the scars of human hearts. These cells express common and unique extracellular matrix and tendon genes that are more specialized to support the mature scar.

Authors

Xing Fu, Hadi Khalil, Onur Kanisicak, Justin G. Boyer, Ronald J. Vagnozzi, Bryan D. Maliken, Michelle A. Sargent, Vikram Prasad, Iñigo Valiente-Alandi, Burns C. Blaxall, Jeffery D. Molkentin

×

Figure 5

Proliferation potential of Tcf21 lineage–traced fibroblasts residing in stable scar.

Options: View larger image (or click on image) Download as PowerPoint
Proliferation potential of Tcf21 lineage–traced fibroblasts residing in ...
(A) Experimental scheme whereby Tcf21MCM/+;R26EGFP mice previously treated with tamoxifen were subjected to MI and then treated with Ang II/PE through osmotic pump 4 weeks after MI. Mice were treated with EdU through daily i.p. injections for 6 days starting at day 2 after pump implantation, and hearts were harvested 4 hours after the last EdU injection for IHC analysis. (B and C) Quantification (B) and representative IHC images from 3 hearts analyzed (C) of EdU+ (white) and Ki67+ (red) Tcf21 lineage–traced (EGFP+) fibroblasts in the infarct region and septum of hearts from Tcf21MCM/+;R26EGFP mice that received treatment as shown in A. Nuclei are shown with DAPI (blue). Scale bars: 20 μm. (D and E) Quantification (D) and representative immunocytochemistry from 3 separate experiments (E) of EdU+ (white) Tcf21 lineage–traced (EGFP+) fibroblasts isolated from uninjured hearts and the infarct region of hearts 4 weeks later. EdU was given for 6 hours with and without TGF-β stimulation. Scale bars: 200 μm. (F) Representative immunocytochemistry images from 3 separate experiments showing αSMA stress fibers (red) in Tcf21 lineage–traced fibroblasts isolated from uninjured hearts and the infarct region of hearts 4 weeks after MI. Cells were also treated with TGF-β for 3 days. Scale bars: 10 μm. (B and D) Data are shown as mean ± SD (n = 3). **P < 0.01, ***P < 0.0001, 2-tailed t test.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts